Zhitong Finance App News, Fussen Pharmaceutical (01652.HK) announced that the marketing application for “Doxazosin Mesylate Sustained Release Tablets” (trademark: Yi Jianping) developed by Henan Fuson Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, has been approved by the China Drug Administration and approved for symptomatic treatment of hypertension and benign prostatic hyperplasia.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.